State-of-the-Art Paper
Genetics of Hypertrophic Cardiomyopathy After 20 Years: Clinical Perspectives

https://doi.org/10.1016/j.jacc.2012.02.068Get rights and content
Under an Elsevier user license
open archive

Hypertrophic cardiomyopathy (HCM) is the most common familial heart disease with vast genetic heterogeneity, demonstrated over the past 20 years. Mutations in 11 or more genes encoding proteins of the cardiac sarcomere (>1,400 variants) are responsible for (or associated with) HCM. Explosive progress achieved in understanding the rapidly evolving science underlying HCM genomics has resulted in fee-for-service testing, making genetic information widely available. The power of HCM mutational analysis, albeit a more limited role than initially envisioned, lies most prominently in screening family members at risk for developing disease and excluding unaffected relatives, which is information not achievable otherwise. Genetic testing also allows expansion of the broad HCM disease spectrum and diagnosis of HCM phenocopies with different natural history and treatment options, but is not a reliable strategy for predicting prognosis. Interfacing a heterogeneous disease such as HCM with the vast genetic variability of the human genome, and high frequency of novel mutations, has created unforeseen difficulties in translating complex science (and language) into the clinical arena. Indeed, proband diagnostic testing is often expressed on a probabilistic scale, which is frequently incompatible with clinical decision making. Major challenges rest with making reliable distinctions between pathogenic mutations and benign variants, and those judged to be of uncertain significance. Genotyping in HCM can be a powerful tool for family screening and diagnosis. However, wider adoption and future success of genetic testing in the practicing cardiovascular community depends on a standardized approach to mutation interpretation, and bridging the communication gap between basic scientists and clinicians.

Key Words

cardiomyopathy
genes
hypertrophy

Abbreviations and Acronyms

GINA
Genetic Information Non-Discrimination Act
HCM
hypertrophic cardiomyopathy
LV
left ventricle/left ventricular
LVH
left ventricular hypertrophy
VUS
variant of uncertain significance

Cited by (0)

Dr. B. J. Maron is an advisor for GeneDx and a grantee of Medtronic. Dr. M. S. Maron has reported that he has no relationships relevant to the contents of this paper to disclose. Dr. Semsarian is the recipient of a Practitioner Fellowship from the National Health & Medical Research Council, Canberra, Australia.